争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 8 条
2021
诺华与达纳-法伯就仿制版 Rydapt 起诉 Dr. Reddy’s
提起诉讼
诺华制药与达纳-法伯癌症研究所提起诉讼，指称 Dr. Reddy’s Laboratories 拟推出的白血病仿制药侵犯了诺华关于 Rydapt 的专利。相关内容是诉讼指控，并非法院认定。
来源摘录
On Friday, Novartis Pharmaceuticals and Dana-Farber Cancer Institute Inc. filed a complaint against fellow pharmaceutical company Dr. Reddy’s Laboratories Inc. in the District of New Jersey. The plaintiff alleged that the defendant is infringing on its patent for the drug Rydapt, used to treat leukemia.
2021
Dr. Reddy's召回处方药泡罩包装
宣布召回
Dr. Reddy's召回约21,400件指定处方药泡罩包装，原因是包装不具儿童防护功能，幼童吞食内容物可能有中毒风险。当时没有事故或伤害报告。
品牌回应
退款或补偿 — Dr. Reddy's
Consumers should immediately store the recalled medications in a safe location out of reach of children and contact Dr. Reddy's for a full refund.
来源摘录
Units: About 21,400
WASHINGTON, Feb. 25, 2021 /PRNewswire/ -- https://cpsc.gov/Recalls/2021/Dr-Reddys-Recalls-Prescription-Drug-Blister-Packages-Due-to-Risk-of-Poisoning
Consumers should immediately store the recalled medications in a safe location out of reach of children and contact Dr. Reddy's for a full refund.
2020
瑞迪博士召回埃索美拉唑镁胶囊
宣布召回
雷迪博士实验室在美国自愿召回1,752瓶仿制埃索美拉唑镁肠溶胶囊。报道称，此次召回是在美国食品药品监督管理局发现产品变色并含有棕色颗粒后进行的。报道指出此次为III类召回。
来源摘录
According to a US Food and Drug Administrationâs (USFDA) report, the recall by the Hyderabad-based company is due to âDiscolourationâ and presence of brown pellets in the product.
As per USFDA norms, the recall has been classified as Class III according to which the product is ânot likely to cause adverse health consequencesâ.
Pharma major Dr Reddyâs Laboratories Ltd has initiated recall of 1m752 bottles of generic Esomeprazole Magnesium delayed release capsules in the US.
2020
Dr. Reddy’s 与 Celgene 就 Revlimid 专利诉讼达成和解
和解
雷迪博士实验室宣布与 Celgene 就 Revlimid 胶囊专利的诉讼达成和解。根据和解协议，Celgene 同意授权雷迪博士实验室在获得监管批准后，自 2022 年 3 月之后某个保密日期起在美国销售数量受限的仿制来那度胺胶囊，并自 2026 年 1 月 31 日起不受数量限制地销售。公告称，在较晚日期之前，获授权的销售均受数量限制，此后数量限制不再适用。
Dr. Reddy’s 宣布与 Celgene 就 Revlimid 胶囊专利的诉讼达成和解。根据和解协议，Celgene 同意授权 Dr. Reddy’s 在获得监管批准后，自 2022 年 3 月之后某个保密日期起在美国销售数量受限的仿制来那度胺胶囊，并自 2026 年 1 月 31 日起不受数量限制地销售。
来源摘录
In settlement of all outstanding claims in the litigation, Celgene has agreed to provide Dr. Reddy's with a license to sell volume-limited amounts of generic lenalidomide capsules in the U.S. beginning on a confidential date after March 2022 subject to regulatory approval.
Dr. Reddy's is also licensed to sell generic lenalidomide capsules in the U.S. without volume limitation beginning on January 31, 2026.
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries (together referred to as "Dr. Reddy's"), today announced the settlement of their litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb (NYSE: BMY), relating to patents for REVLIMID® (lenalidomide) Capsules.
2020
雷迪博士实验室披露勒索软件攻击
问题披露
雷迪博士实验室表示，该公司此前一周发现的网络攻击涉及勒索软件。公司称已隔离受影响的IT服务。公司还表示，调查尚未确定事件是否涉及个人身份信息泄露。
Dr. Reddy’s Laboratories表示，该公司上周发现的网络攻击涉及勒索软件。公司称已隔离受影响的IT服务，调查尚未确定事件是否涉及个人身份信息泄露。
品牌回应
调查 — Dr. Reddy’s Laboratories
Following the incident, the company said it had engaged leading outside cybersecurity experts and launched a comprehensive containment and remediation effort as well as investigation to address the incident.
整改 — Dr. Reddy’s Laboratories
Following the incident, the company said it had engaged leading outside cybersecurity experts and launched a comprehensive containment and remediation effort as well as investigation to address the incident.
来源摘录
Dr. Reddyâs Laboratories on Wednesday said the cyber attack it had detected on last week involved a ransomware attack.
2019
法院驳回Dr. Reddy’s在VIMOVO专利诉讼中的简易判决动议
裁决
新泽西联邦地区法院驳回Dr. Reddy’s Laboratories在涉及两项VIMOVO专利的Nuvo相关诉讼中提出的简易判决动议，因此专利侵权诉讼将继续。Nuvo表示其认为相关专利有效且可执行；报道所述裁定针对该动议，并非对侵权问题作出的最终裁决。
来源摘录
today announced that the United States District Court for the District of New Jersey has denied a motion for summary judgment filed by Dr. Reddy's Laboratories Inc. (DRL). As a result, the patent infringement litigation against DRL, involving Nuvo Pharmaceuticals (Ireland) DAC's (Nuvo Ireland) U.S. Patent Nos. 8,858,996 and 9,161,920 (the '996 and '920 patents), will continue.
We believe these patents are valid and enforceable and will continue to enforce Nuvo Ireland's rights against DRL.
2019
瑞迪博士在美国召回雷尼替丁批次产品
宣布召回
瑞迪博士因确认其雷尼替丁产品受 NDMA 污染且含量超过 FDA 规定水平，在美国自愿召回若干批次产品。召回于 10 月 1 日开始。
来源摘录
The recall has been initiated at the retail level for over-the-counter products and at the consumer level for prescription products of all of its ranitidine medications sold in the US due to confirmed contamination with NDMA above levels established by the USFDA, Dr Reddy's said in a filing to the BSE.
Pharma major Dr. Reddyâs Laboratories is recalling all of its ranitidine medications sold in the U.S. due to confirmed contamination with N-Nitrosodimethylamine (NDMA) above the levels established by the U.S. Food and Drug Administration (USFDA).
Dr Reddy's Laboratories on Wednesday said it has initiated a voluntary nationwide recall of all its ranitidine medications sold in the US due to contamination with probable cancer causing N-Nitrosodimethylamine (NDMA).
1995